Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026986 (myelodysplastic syndrome)
 14,926 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We investigated retrospectively 992 children with central nervous system tumors who were treated at our center between 1970 and 2004. All of the patients were treated by surgery, chemotherapy, and/or radiotherapy. Six patients developed second malignant neoplasms, and their clinical and histopathologic characteristics are reviewed in this article. The second malignant neoplasms were diagnosed as non-Hodgkin lymphoma, myelodysplastic syndrome, basal cell carcinoma, malignant melanoma, Kaposi sarcoma, and high-grade neuroectodermal tumor. The initial diagnoses were ependymoblastoma in one, medulloblastoma in three, and low-grade astrocytoma in two patients. The median latency time was 3.03 years (range 0.39-22.93 years). The outcome varied according to the histopathologic type of the second tumor. The patients who developed non-Hodgkin lymphoma and myelodysplastic syndrome died of progressive disease. The patients with second skin neoplasms are alive as of the time of this writing. The patient with Kaposi sarcoma developed one of the rare reported second malignant neoplasms following a primary brain tumor in childhood. A wide spectrum of second malignant neoplasms was detected after treatment of primary brain tumors with surgery, radiotherapy, and chemotherapy. Long-term follow-up is therefore necessary for the child who has survived a primary central nervous system tumor.
 ...
PMID:Second malignant neoplasms following the treatment of brain tumors in children. 1690 54

This study summarizes the development and progress of the pediatric Hematopoietic Stem Cell Transplantation (HSCT) program in Puerto Rico. Data from the two pediatric transplant centers was collected from July 1994 through December 2009. Overall, in the last 15 years 97 transplants have been performed to 87 children and young adults. These included 55 males and 32 females, aged between 1 and 38 years of age. The diagnosis included: acute leukemia, chronic leukemia, myelodysplasia, aplastic anemia, histiocytosis, neuroblastoma, lymphomas, PNET, Wilms tumor, and desmoplastic round cell tumor. Sources of hematopoietic stem cells for transplantation included: 5 autologous bone marrow, 23 allogeneic bone marrow using HLA matched sibling; 18 allogeneic peripheral blood stem cell (PBSC) using HLA-matched sibling and one syngeneic PBSC; 4 haploidentical T-cell depleted bone marrow transplant and 47 autologous PBSC. The results in the past 15 years are encouraging and conform that HSCT is a valuable treatment option in our pediatric population to no other alternative therapy. Our experience compares to those published by others with a 15-year overall survival of 48%. In this same group, the transplant related mortality was 14.9% comparable to published experience in Europe and USA.
 ...
PMID:Pediatric hematopoietic stem cell transplantation: fifteen year experience in Puerto Rico. 2388 68